TCGA-E2-A15S-01A-11R-A115-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 14
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- G2M_CHECKPOINT+0.440
- MYC_TARGETS_V1+0.330
- DNA_REPAIR+0.310
- MITOTIC_SPINDLE+0.240
- SPERMATOGENESIS+0.190
- PANCREAS_BETA_CELLS+0.060
- PEROXISOME+0.060
- MYC_TARGETS_V2+0.050
- UNFOLDED_PROTEIN_RESPONSE+0.040
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.620
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.590
- INTERFERON_GAMMA_RESPONSE-0.590
- INFLAMMATORY_RESPONSE-0.560
- INTERFERON_ALPHA_RESPONSE-0.560
- TNFA_SIGNALING_VIA_NFKB-0.520
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.510
- IL6_JAK_STAT3_SIGNALING-0.500
- COMPLEMENT-0.490
- ANGIOGENESIS-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-66-2793-01A-01R-1201-07 | — | cohortMD1 | 0.945 |
| 2 | BS_HTEPAKCM | medulloblastoma | — | 0.942 |
| 3 | BS_GNV89A5P | medulloblastoma | — | 0.941 |
| 4 | BS_Y8D1F5WW | medulloblastoma | — | 0.936 |
| 5 | BS_NKRYMHEP | medulloblastoma | — | 0.933 |
| 6 | BS_EFE4YEK3 | medulloblastoma | — | 0.932 |
| 7 | BS_BSV07M7Z | medulloblastoma | — | 0.931 |
| 8 | BS_J8G4SH4Z | medulloblastoma | — | 0.930 |
| 9 | BS_QPPPGYP4 | medulloblastoma | — | 0.929 |
| 10 | BS_4CP4T22V | medulloblastoma | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.050 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |